journal article·2021-03-23

In Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design

Paula M. Cevaal, Abdalla Ali, Ewa Czuba-Wojnilowicz, Jori Symons, Sharon R. Lewin, Christina Cortez-Jugo, Frank Caruso

ACS Nano· Volume 15· Issue 3
Publisher page

Abstract

T cells play an important role in immunity and repair and are implicated in diseases, including blood cancers, viral infections, and inflammation, making them attractive targets for the treatment and prevention of diseases. Over recent years, the advent of nanomedicine has shown an increase in studies that use nanoparticles as carriers to deliver therapeutic cargo to T cells for ex vivo and in vivo applications. Nanoparticle-based delivery has several advantages, including the ability to load and protect a variety of drugs, control drug release, improve drug pharmacokinetics and biodistribution, and site- or cell-specific targeting. However, the delivery of nanoparticles to T cells remains a major technological challenge, which is primarily due to the nonphagocytic nature of T cells. In this review, we discuss the physiological barriers to effective T cell targeting and describe the different approaches used to deliver cargo-loaded nanoparticles to T cells for the treatment of disease such as T cell lymphoma and human immunodeficiency virus (HIV). In particular, engineering strategies that aim to improve nanoparticle internalization by T cells, including ligand-based targeting, will be highlighted. These nanoparticle engineering approaches are expected to inspire the development of effective nanomaterials that can target or manipulate the function of T cells for the treatment of T cell-related diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · CAR-T cell therapy research · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia

Victorian Infectious Diseases, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia

Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria 3004, Australia

Funding

National Health and Medical Research Council · Centre of Excellence in Convergent Bio-Nano Science and Technology, Australian Research Council

References (100+)

Show source-provided references
1. 10.1016/j.immuni.2018.01.00710.1016/j.immuni.2018.01.007 ↗
2. 10.3389/fimmu.2020.0109010.3389/fimmu.2020.01090 ↗
3. 10.1016/j.immuni.2014.12.02410.1016/j.immuni.2014.12.024 ↗
4. 10.1111/imr.1275710.1111/imr.12757 ↗
5. 10.1038/icb.2015.11810.1038/icb.2015.118 ↗
6. 10.3389/fmicb.2018.0315810.3389/fmicb.2018.03158 ↗
7. 10.1038/sj.leu.240468310.1038/sj.leu.2404683 ↗
8. 10.1073/pnas.101514810810.1073/pnas.1015148108 ↗
9. 10.1093/infdis/jix20810.1093/infdis/jix208 ↗
10. 10.1111/imr.1204410.1111/imr.12044 ↗
11. 10.1016/j.immuni.2009.05.00110.1016/j.immuni.2009.05.001 ↗
12. 10.1038/nrc125210.1038/nrc1252 ↗
13. 10.1016/j.jconrel.2014.03.05010.1016/j.jconrel.2014.03.050 ↗
14. 10.1038/s41467-017-01830-810.1038/s41467-017-01830-8 ↗
15. 10.1126/scitranslmed.aaa544710.1126/scitranslmed.aaa5447 ↗
16. 10.1038/nri.2017.11210.1038/nri.2017.112 ↗
17. 10.1126/science.aaf675610.1126/science.aaf6756 ↗
18. 10.1038/s41577-018-0042-210.1038/s41577-018-0042-2 ↗
19. 10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
20. 10.1038/bcj.2017.5310.1038/bcj.2017.53 ↗
21. 10.1038/487439a10.1038/487439a ↗
22. 10.1016/j.virusres.2017.07.02010.1016/j.virusres.2017.07.020 ↗
23. 10.1056/NEJMoa130066210.1056/NEJMoa1300662 ↗
24. 10.1038/s41577-019-0269-610.1038/s41577-019-0269-6 ↗
25. 10.1038/srep3074910.1038/srep30749 ↗
26. 10.1016/j.jconrel.2016.01.04410.1016/j.jconrel.2016.01.044 ↗
27. 10.2217/nnm.11.16210.2217/nnm.11.162 ↗
28. 10.1371/journal.pone.015157210.1371/journal.pone.0151572 ↗
29. 10.1007/s11095-016-1958-510.1007/s11095-016-1958-5 ↗
30. 10.1016/j.ebiom.2016.04.02810.1016/j.ebiom.2016.04.028 ↗
31. 10.1016/j.actbio.2020.04.01510.1016/j.actbio.2020.04.015 ↗
32. 10.1016/j.ymthe.2019.03.01210.1016/j.ymthe.2019.03.012 ↗
33. 10.1038/mto.2016.1110.1038/mto.2016.11 ↗
34. 10.3390/genes1110111310.3390/genes11101113 ↗
35. 10.1038/s41598-017-00462-810.1038/s41598-017-00462-8 ↗
36. 10.1126/science.aat501110.1126/science.aat5011 ↗
37. 10.1073/pnas.151250311210.1073/pnas.1512503112 ↗
38. 10.1038/nmat164510.1038/nmat1645 ↗
39. 10.1146/annurev-virology-092818-01553010.1146/annurev-virology-092818-015530 ↗
40. 10.1089/hum.2006.17.25310.1089/hum.2006.17.253 ↗
41. 10.1038/sj.gt.330236410.1038/sj.gt.3302364 ↗
42. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
43. 10.15585/mmwr.mm6950e210.15585/mmwr.mm6950e2 ↗
44. 10.15585/mmwr.mm695152e210.15585/mmwr.mm695152e2 ↗
45. 10.1016/j.jconrel.2018.02.04310.1016/j.jconrel.2018.02.043 ↗
46. 10.3390/ijms2003063610.3390/ijms20030636 ↗
47. 10.1073/pnas.150353211210.1073/pnas.1503532112 ↗
48. 10.1016/j.cellimm.2013.06.01110.1016/j.cellimm.2013.06.011 ↗
49. 10.1002/btm2.1014310.1002/btm2.10143 ↗
50. 10.1088/1361-6528/ab5bc810.1088/1361-6528/ab5bc8 ↗
51. 10.1016/j.ejmech.2019.01.00710.1016/j.ejmech.2019.01.007 ↗
52. 10.12691/nnr-4-2-510.12691/nnr-4-2-5 ↗
53. 10.2174/13892002160315081212422110.2174/138920021603150812124221 ↗
54. 10.3389/fbioe.2020.0004810.3389/fbioe.2020.00048 ↗
55. 10.2147/IJN.S18472310.2147/IJN.S184723 ↗
56. 10.3389/fchem.2019.0029010.3389/fchem.2019.00290 ↗
57. 10.1021/bp049582510.1021/bp0495825 ↗
58. 10.1021/bm501713910.1021/bm5017139 ↗
59. 10.1039/C6NR00506C10.1039/C6NR00506C ↗
60. 10.1007/s12013-018-0863-410.1007/s12013-018-0863-4 ↗
61. 10.1016/j.cis.2019.10203710.1016/j.cis.2019.102037 ↗
62. 10.1002/anie.20200208910.1002/anie.202002089 ↗
63. 10.1016/S0169-409X(97)00110-510.1016/S0169-409X(97)00110-5 ↗
64. 10.1073/pnas.92.16.729710.1073/pnas.92.16.7297 ↗
65. 10.1002/med.2150610.1002/med.21506 ↗
66. 10.1016/j.jconrel.2019.08.02410.1016/j.jconrel.2019.08.024 ↗
67. 10.1002/adma.20190462510.1002/adma.201904625 ↗
68. 10.1016/j.cocis.2013.06.00210.1016/j.cocis.2013.06.002 ↗
69. 10.3389/fchem.2014.0004810.3389/fchem.2014.00048 ↗
70. 10.1155/2015/19817510.1155/2015/198175 ↗
71. 10.1002/1521-4095(200101)13:1<11::AID-ADMA11>3.0.CO;2-N10.1002/1521-4095(200101)13:1<11::AID-ADMA11>3.0.CO;2-N ↗
72. 10.1002/anie.20046213510.1002/anie.200462135 ↗
73. 10.3390/polym303137710.3390/polym3031377 ↗
74. 10.3390/pharmaceutics904005310.3390/pharmaceutics9040053 ↗
75. 10.2174/138161282566619042516342410.2174/1381612825666190425163424 ↗
76. 10.1016/j.addr.2019.08.00610.1016/j.addr.2019.08.006 ↗
77. 10.1016/j.msec.2018.03.00210.1016/j.msec.2018.03.002 ↗
78. 10.1016/j.cell.2012.06.04210.1016/j.cell.2012.06.042 ↗
79. 10.1039/C5CS00541H10.1039/C5CS00541H ↗
80. 10.1038/nnano.2013.18110.1038/nnano.2013.181 ↗
81. 10.1002/adma.20180574010.1002/adma.201805740 ↗
82. 10.1016/j.nantod.2015.06.00610.1016/j.nantod.2015.06.006 ↗
83. 10.1021/acsnano.9b0723310.1021/acsnano.9b07233 ↗
84. 10.1038/nrneph.2016.15610.1038/nrneph.2016.156 ↗
85. 10.1002/smll.20130354010.1002/smll.201303540 ↗
86. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
87. 10.2217/nnm.14.16010.2217/nnm.14.160 ↗
88. 10.1126/science.266508110.1126/science.2665081 ↗
89. 10.1002/adma.20080182610.1002/adma.200801826 ↗
90. 10.1021/nn506157810.1021/nn5061578 ↗
91. 10.1039/C6PY01332E10.1039/C6PY01332E ↗
92. 10.1021/acsami.6b1594210.1021/acsami.6b15942 ↗
93. 10.1021/acsnano.0c0603310.1021/acsnano.0c06033 ↗
94. 10.1021/acs.langmuir.8b0211710.1021/acs.langmuir.8b02117 ↗
95. 10.1021/acsnano.9b0055210.1021/acsnano.9b00552 ↗
96. 10.1016/j.jconrel.2019.08.01710.1016/j.jconrel.2019.08.017 ↗
97. 10.2147/IJN.S16880810.2147/IJN.S168808 ↗
98. 10.1016/j.cocis.2017.06.00410.1016/j.cocis.2017.06.004 ↗
99. 10.1093/protein/gzt02310.1093/protein/gzt023 ↗
100. 10.1016/j.ijpharm.2019.11862810.1016/j.ijpharm.2019.118628 ↗